

Axillary Hyperhidrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/A56EEF979AA9EN.html>

Date: May 2024

Pages: 138

Price: US\$ 6,499.00 (Single User License)

ID: A56EEF979AA9EN

Abstracts

The 7 major axillary hyperhidrosis markets reached a value of US\$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 2.1 Billion by 2034, exhibiting a growth rate (CAGR) of 5.53% during 2024-2034.

The axillary hyperhidrosis market has been comprehensively analyzed in IMARC's new report titled "Axillary Hyperhidrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Axillary hyperhidrosis, also called excessive underarm sweating, is a medical condition characterized by abnormal and uncontrollable production of sweat in the armpit region. This disorder can significantly impact a patient's quality of life, leading to embarrassment, social anxiety, and discomfort. The symptoms of the ailment include persistent and profuse sweating in the armpits, even in cool or relaxed conditions, which may result in unpleasant body odor and damp clothing. Diagnosing axillary hyperhidrosis involves a comprehensive evaluation by a healthcare professional. The doctor will typically conduct a physical examination and review the patient's clinical history to rule out any underlying medical problems that could be contributing to excessive sweating. Moreover, various other workups, such as the starch-iodine test, are utilized to confirm the diagnosis and assess the extent of sweat production in the affected area. Early detection and appropriate intervention of the disease can aid patients in leading a more comfortable and confident life.

The rising prevalence of endocrine disorders, which can result in overactivation of the sweat glands in the armpits, leading to excessive and uncontrollable sweating in the affected region, is primarily driving the axillary hyperhidrosis market. In addition to this, the increasing incidence of inadequate treatment or lack of proper immunization against

the condition, that can further enhance the risk of complications and exacerbate the demand for effective solutions, is also creating a positive outlook for the market. Moreover, the widespread adoption of several effective drugs, including topical antiperspirants, iontophoresis, botulinum toxin injections, etc., to alleviate the symptoms and manage the underlying causes of axillary hyperhidrosis is further bolstering the market growth. Apart from this, the rising usage of innovative treatments, such as neuromuscular blockers, since they work by interrupting nerve impulses at the affected myoneural junction to minimize excessive sweating, muscle spasms, and discomfort in individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of axillary hyperhidrosis immune globulin (AHIG) therapy, which aims to neutralize bacterial toxins and prevent their harmful effects by providing immediate passive immunity against pathogens, is expected to drive the axillary hyperhidrosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the axillary hyperhidrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for axillary hyperhidrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the axillary hyperhidrosis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the axillary hyperhidrosis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the axillary hyperhidrosis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current axillary hyperhidrosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the axillary hyperhidrosis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the axillary hyperhidrosis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the axillary hyperhidrosis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of axillary hyperhidrosis across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of axillary hyperhidrosis by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of axillary hyperhidrosis by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with axillary hyperhidrosis across the seven major markets?

What is the size of the axillary hyperhidrosis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of axillary hyperhidrosis?

What will be the growth rate of patients across the seven major markets?

Axillary Hyperhidrosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for axillary hyperhidrosis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the axillary hyperhidrosis market?

What are the key regulatory events related to the axillary hyperhidrosis market?

What is the structure of clinical trial landscape by status related to the axillary hyperhidrosis market?

What is the structure of clinical trial landscape by phase related to the axillary hyperhidrosis market?

What is the structure of clinical trial landscape by route of administration related to the axillary hyperhidrosis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 AXILLARY HYPERHIDROSIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 AXILLARY HYPERHIDROSIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 AXILLARY HYPERHIDROSIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 AXILLARY HYPERHIDROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 AXILLARY HYPERHIDROSIS - UNMET NEEDS

10 AXILLARY HYPERHIDROSIS - KEY ENDPOINTS OF TREATMENT

11 AXILLARY HYPERHIDROSIS - MARKETED PRODUCTS

- 11.1 List of Axillary Hyperhidrosis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Botox (Onabotulinumtoxin A)- Abbvie
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Qbrexza (Glycopyrronium)- Dermira
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 AXILLARY HYPERHIDROSIS - PIPELINE DRUGS

12.1 List of Axillary Hyperhidrosis Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Drug Name – Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. AXILLARY HYPERHIDROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. AXILLARY HYPERHIDROSIS – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 AXILLARY HYPERHIDROSIS - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Axillary Hyperhidrosis - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Axillary Hyperhidrosis - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States

- 15.3.1 Axillary Hyperhidrosis - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Axillary Hyperhidrosis - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Axillary Hyperhidrosis - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Axillary Hyperhidrosis - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Axillary Hyperhidrosis - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Axillary Hyperhidrosis - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Axillary Hyperhidrosis - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Axillary Hyperhidrosis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Axillary Hyperhidrosis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Axillary Hyperhidrosis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Axillary Hyperhidrosis - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Axillary Hyperhidrosis - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Axillary Hyperhidrosis - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Axillary Hyperhidrosis - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Axillary Hyperhidrosis - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Axillary Hyperhidrosis - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Axillary Hyperhidrosis - Access and Reimbursement Overview

16 AXILLARY HYPERHIDROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 AXILLARY HYPERHIDROSIS MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 AXILLARY HYPERHIDROSIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Axillary Hyperhidrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/A56EEF979AA9EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A56EEF979AA9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

